Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Arthritis Care & Research|September 18, 2018
Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled TrialDaniel H Solomon, Zhi Yu, Jeffrey N Katz, et al.
The Journal of Rheumatology|October 3, 2017
Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease ActivityLeslie R Harrold, Bradley S Stolshek, Sabrina Rebello, et al.
The Journal of Rheumatology|January 17, 2019
Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor InhibitorAlexis Ogdie, J Lynn Palmer, Jeffrey Greenberg, et al.
Pharmaceutical Statistics|June 10, 2025
Applying Bias Correction Methods to Build Hybrid Controls Using Real-World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid ArthritisHeather J Litman, Kristin M Sheffield, Oksana Pugach, et al.
Arthritis and Rheumatism|September 29, 2011
Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendationsLeslie R Harrold, J Timothy Harrington, Jeffrey R Curtis, et al.
Clinical Rheumatology|March 9, 2017
Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registryLeslie R Harrold, Bradley S Stolshek, Sabrina Rebello, et al.
The Journal of Rheumatology|August 3, 2019
Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based RegistryLeslie R Harrold, Jenny Griffith, Patrick Zueger, et al.
Rheumatology and Therapy|January 12, 2018
Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort StudyCynthia J Larmore, Natalie N Boytsov, Carol L Gaich, et al.
Rheumatology and Therapy|May 28, 2021
Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RALeslie R Harrold, Joshua Bryson, Thomas Lehman, et al.
Arthritis Care & Research|April 23, 2019
Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid ArthritisJustin K Owensby, Lang Chen, Ronan O'Beirne, et al.
Pageof 13